Abstract: Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1, including all geometric and stereoisomers, tautomers, A-oxides, and salts thereof, wherein E, L, J, A and T are as defined in the disclosure; and (b) at least one additional fungicidal compound. Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1, an A-oxide, or salt thereof (e.g., as a component in the aforesaid composition). Also disclosed is a composition comprising: (a) at least one compound selected from the compounds of Formula 1 described above, A-oxides, and salts thereof; and at least one invertebrate pest control compound or agent.

Abstract: Various embodiments include an automobile network device that includes a descriptor sorting engine (DSE). The DSE may include a direct memory access (DMA) controller, a memory organized by channel clusters that each include a plurality of first-in first-out (FIFO) memories, a timer, and a time stamp (TS) sorting logic component. The DMA controller may be configured to pull timestamp-pointer pairs from packet descriptors stored in an unsorted descriptor ring memory, store the timestamp-pointer pairs in the FIFO memories, trigger the TS sorting logic component to reorder the timestamp-pointer pairs in the FIFO memories so that they are sorted in ascending order, use the sorted timestamp-pointer pairs in the FIFO memories to read the packet descriptors stored in an unsorted descriptor ring memory, and store the packet descriptors in a sorted descriptor ring memory.

Abstract: In an embodiment, a method comprises: establishing, by a wireless wearable computer worn by a user, a wireless communication connection with a fitness machine; obtaining machine data from the fitness machine while the user is engaged in a workout session on the fitness machine; obtaining, from a heart rate sensor of the wireless device, heart rate data of the user; determining a calibrated maximal oxygen consumption of the user based on the heart rate data and the machine data; determining a heart rate caloric expenditure based on the heart rate data and the calibrated maximal oxygen consumption of the user; and providing information corresponding to the heart rate caloric expenditure for presentation.

Abstract: Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, L and J are as defined in the disclosure and (b) at least one additional fungicidal compound. Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1, an N-oxide, or salt thereof (e.g., as a component in the aforesaid composition). Also disclosed is a composition comprising: (a) at least one compound selected from the compounds of Formula 1 described above, N-oxides, and salts thereof; and at least one invertebrate pest control compound or agent.

Abstract: Techniques are disclosed for facilitating disabling an alarm in response to particular types of activity-indicative data. More specifically, activity-indicative data (e.g., measurements obtained by an electronic device) can be detected prior to a preset alarm time. Upon determining, based on the activity-indicative data, that a wakefulness condition is satisfied, the alarm can be disabled such that the alarm stimuli is not to be presented at the preset alarm time.

Abstract: Methods of treating a stress-related disease or disorder such as PTSD, decreasing side effects of 3,4-methylenedioxy-methamphetamine (MDMA), inducing neurite outgrowth, inducing structural neuroplasticity, or increasing brain-derived neurotrophic factor (BDNF) levels, comprising administering to a subject effective amounts of a composition comprising R(?)-3,4-methylenedioxymethamphetamine (R(?)-MDMA) are disclosed. Also disclosed are pharmaceutical compositions comprising R(?)-MDMA and a pharmaceutically acceptable carrier.

Abstract: Methods and systems for enhanced mobility for voice calls in a new radio band are disclosed. According to an implementation, data services and/or multimedia services may be provided to a user equipment (UE) through a 5G new radio (NR) in a standalone (SA) mode. During the ongoing data service, the UE may receive a voice call in the current NR band. If the current NR band does not support the voice call, the UE may search and acquire a new NR band capable of providing the voice call. The UE may further set the new NR band as the serving cell and transfer the current data radio bearers (DRBs) assigned for the ongoing data service to the new NR band. While the UE receives new DRBs assigned for the voice call, the UE continues the data service and the voice call in the new NR band.

Abstract: Connection configuration for Fourth Generation (4G) and Fifth Generation (5G) converged deployment may be provided. A User Equipment (UE) Usage Type (UUT) mapping may be stored, wherein the UUT mapping includes an Attribute Value Pair (AVP) for one or more UUTs. A connection to a 5G network from a 4G network may be received from a UE, wherein the connection comprises subscription information that includes a UUT the UE is subscribed to. In response to receiving the UUT, a subscriber profile for the UE in a converged packet core may be determined using the UUT mapping, and the configuration of the connection for the UE may be established based on the determined subscriber profile.

Abstract: Particular embodiments described herein provide for an electronic device that can be configured to include a fan where the fan blades are decoupled from the center shaft. The fan can include a center shaft, a motor coil support, motor coils coupled to the motor coil support, a rotator coupled to the center shaft, and fan blades coupled to the rotator, where rotation of the fan blades is decoupled from the center shaft by the rotator. A blade support can be coupled to the rotator, where the blade support couples the fan blades to the rotator and magnets can be coupled to the blade support. In an example, the rotator can include an inner, an outer race, and bearings.

Abstract: Compounds having activity as inhibitors of ENPP1 are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein L, R1, R2a, R2b, R2c, R2d, R2e and n are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating disorders associated with ENPP1, including uncontrolled cellular proliferation, cancer and virial or bacterial infections in a mammal.

Abstract: Novel images may be generated using an image generator implemented on a processor. The image generator may receive as input neural features selected from a neural texture atlas. The image generator may also receive as input one or more position guides identifying position information for a plurality of input image pixels. The novel images may be evaluated using an image discriminator to determine a plurality of optimization values by comparing each of the plurality of novel images with a respective one of a corresponding plurality of input images. Each of the novel images may be generated from a respective camera pose relative to an object identical to that of the respective one of the corresponding plurality of input images. The image generator and the neural features may be updated based on the optimization values and stored on a storage device.

Abstract: Techniques for providing a QA run cycle and report generation system are provided. In one technique, a user interface (UI) tool retrieves first software testing result data that was generated based on a first type of software test of a software build. The UI tool also retrieves second software testing result data that was generated based on a second type of software test of the software build. In response to receiving first input that selects the first software testing result data, the UI tool updates a UI to present first data that is based on a portion of the first software testing result data. In response to receiving the second input that selects the second software testing result data, the UI tool updates the UI to present second data that is based on a portion of the second software testing result data.

Abstract: The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.

Abstract: Methods, systems and computer-program products are directed to a Privacy Engine for evaluating initial electronic documents to identify document content categories for portions of content within the electronic documents, with respect to extracted document structures and document positions, that may include privacy information for possible redaction via visual modification. The Privacy Engine builds a content profile based on detecting information at respective portions of electronic document content that indicate one or more pre-defined categories and/or sub-categories. For each respective portion of electronic document content, the Privacy Engine applies a machine learning model that corresponds with the indicated category (or categories and sub-categories) to determine a probability value of whether the respective portion of content includes data considered likely to be privacy information.

Abstract: Compounds having activity as anti-cancer agents are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or tautomer, thereof, wherein X, Y, R1, R2, R3R4, R5 and L are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating a CDK7-dependent disease (e.g., cancer).

Abstract: Various embodiments may provide non-isolated single-input dual-output (SIDO) bi-directional buck-boost direct current (DC) to DC (DC-DC) converters. Various embodiments may provide a method for controlling a buck duty cycle of the non-isolated SIDO bi-directional buck-boost DC-DC converter such that a first voltage measured across a first portion of the non-isolated SIDO bi-directional buck-boost DC-DC converter is maintained at less than a voltage of a first load and a second voltage measured across a second portion of the non-isolated SIDO bi-directional buck-boost DC-DC converter is maintained at less than a voltage of a second load.

Abstract: The invention relates to a polypropylene based nucleating agent masterbatch and a preparation method thereof. The masterbatch is composed of, by weight, 0.1 to 60 wt. % of bis-2-hydroxyethylene terephthalate (BHETA) based nucleating agent, 40 to 99.9 wt. % parts of polypropylene. The present invention discloses a process for preparation of a polypropylene masterbatch by mixing polypropylene with a nucleating agent as represented in FIG. 1. According to the invention, the prepared polypropylene masterbatch has the advantages of being a masterbatch which can be added in any grade of polypropylene, does not cause inhalation hazards while handling, is easy to handle and has improved dispersion in the base polypropylene.

Abstract: The invention relates to a polypropylene based nucleating agent masterbatch and a preparation method thereof. The masterbatch is composed of, by weight, 2 to 60 wt. % of diurea based nucleating agent, 40 to 98 wt. % parts of polypropylene resin. The present invention discloses a process for preparation of a polypropylene masterbatch by mixing polypropylene with a nucleating agent as represented in FIG. 2. According to the invention, the prepared polypropylene masterbatch has the advantages of being a masterbatch which can be added in any grade of polypropylene, does not cause inhalation hazards while handling, is easy to handle and has improved dispersion in the base polypropylene.

Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.

Abstract: The disclosure provides compositions comprising Salvinorin A or a derivative of Salvinorin A for use in treating neurological diseases and conditions.